Breaking News Instant updates and real-time market news.

2022-07-06 11:05:02 ATHE Alterity Therapeutics / + 11:05 07/06/22 07/06 11:05 07/06/22 11:05	Alterity Therapeutics doses first patient in ATH434 Phase 2 trial Alterity Therapeutics announced the first patient has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy, a rare and highly debilitating Parkinsonian disorder .The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA. The study will explore the effect of ATH434 treatment on imaging and protein biomarkers, such as aggregating alpha-synuclein and excess iron, which are important contributors to MSA pathology. Clinical and biomarker endpoints will permit comprehensive assessment of ATH434 efficacy along with characterization of safety and pharmacokinetics. The study is expected to enroll approximately 60 adult patients to receive one of two doses of ATH434 or placebo. Patients will receive treatment for 12 months which will provide an opportunity to detect changes in efficacy endpoints to optimize design of a definitive Phase 3 study.

2022-07-06 11:05:02

ATHE

Alterity Therapeutics

/ +

11:05

07/06/22

07/06

11:05

07/06/22

11:05

Alterity Therapeutics doses first patient in ATH434 Phase 2 trial

Alterity Therapeutics announced the first patient has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy, a rare and highly debilitating Parkinsonian disorder .The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA. The study will explore the effect of ATH434 treatment on imaging and protein biomarkers, such as aggregating alpha-synuclein and excess iron, which are important contributors to MSA pathology. Clinical and biomarker endpoints will permit comprehensive assessment of ATH434 efficacy along with characterization of safety and pharmacokinetics. The study is expected to enroll approximately 60 adult patients to receive one of two doses of ATH434 or placebo. Patients will receive treatment for 12 months which will provide an opportunity to detect changes in efficacy endpoints to optimize design of a definitive Phase 3 study.

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Rockley Photonics price target lowered to $14 from $21 at Cowen » 07:37 08/12/22 08/12 07:37 08/12/22 07:37 RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) Cowen analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 08/11/22 Rockley Photonics sees FY22 core product revenue $5M-$10M 08/09/22 Rockley Photonics gets first commercial order for Rockley Bioptx band 07/26/22 Rockley Photonics announces strategic partnership with contract research group 06/16/22 Rockley customer begins evaluation program using its sensing technology RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 06:37 Today Baird Rockley Photonics downgraded to Neutral from Outperform at Baird 06/08/22 Baird to hold a conference 06/07/22 Baird to hold a conference 05/13/22 Needham Rockley Photonics price target lowered to $4 from $8 at Needham RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 08/11/22 Rockley Photonics reports Q2 adjusted EPS (82c), consensus (25c) 06/15/22 Rockley Photonics affirms FY22 revenue guidance 05/12/22 Rockley Photonics reports Q1 adjusted EPS (28c), consensus (25c) 03/08/22 Rockley Photonics sees FY22 revenue $20M-$30M, consensus $24.87M RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 04/22/22 Rockley Photonics falls after Iceberg Research reveals short position 04/22/22 Iceberg Research announces short position in Rockley Photonics RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 04/22/22 What You Missed On Wall Street On Friday 04/22/22 What You Missed On Wall Street This Morning 03/08/22 Fly Intel: After-Hours Movers RKLY Rockley Photonics $2.00 / -0.1 (-4.76%) 06/22/22 Largest borrow rate increases among liquid names 05/12/22 Rockley Photonics Holdings options imply 14.2% move in share price post-earnings 03/08/22 Rockley Photonics Holdings options imply 13.6% move in share price post-earnings
Earnings	Axcella Health reports Q2 EPS (40c), consensus (38c) » 07:37 08/12/22 08/12 07:37 08/12/22 07:37 AXLA Axcella Health $2.34 / + (+0.00%) As of June 30, cash, cash… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings AXLA Axcella Health $2.34 / + (+0.00%) 08/02/22 Axcella Health reports results from Phase 2a investigation for AXA1125 05/26/22 Axcella done enrolling of trial for long COVID and prioritize portfolio 02/14/22 Axcella Health receives fast track designation from FDA for AXA1125 AXLA Axcella Health $2.34 / + (+0.00%) 08/03/22 H.C. Wainwright Axcella Health price target lowered to $8 from $14 at H.C. Wainwright 05/09/22 Chardan Axcella Health price target lowered to $7 from $12 at Chardan 10/12/21 Noble Capital Axcella Health initiated with an Outperform at Noble Capital 09/22/21 Goldman Sachs Axcella Health downgraded to Neutral from Buy at Goldman Sachs AXLA Axcella Health $2.34 / + (+0.00%) 05/05/22 Axcella reports Q1 EPS (46c), consensus (39c) 03/30/22 Axcella Health reports Q4 EPS (46c), consensus (45c)
Recommendations	Kore Group price target lowered to $9 from $12.50 at Cowen » 07:35 08/12/22 08/12 07:35 08/12/22 07:35 KORE Kore Group $2.71 / -0.03 (-1.09%) Cowen analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly KORE Kore Group $2.71 / -0.03 (-1.09%) 06/06/22 Kore Group rises 13.9% 03/30/22 Kore Group rises 9.6% 03/22/22 Kore Group promotes Paul Holtz to CFO 02/17/22 Kore Group acquires Business Mobility Partners and SIMON IoT KORE Kore Group $2.71 / -0.03 (-1.09%) 05/17/22 Deutsche Bank Kore Group price target lowered to $6 from $7.50 at Deutsche Bank 04/12/22 Morgan Stanley Kore Group price target lowered to $6.50 from $7.50 at Morgan Stanley 04/12/22 Morgan Stanley Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious 03/10/22 Cowen Kore Group price target lowered to $12.50 from $18 at Cowen KORE Kore Group $2.71 / -0.03 (-1.09%) 08/11/22 Kore Group still sees 2022 revenue $260M-$265M, consensus $267.04M 08/11/22 Kore Group reports Q2 EPS (15c), consensus (7c) 05/16/22 Kore Group reaffirms FY22 revenue view $260M-$265M, consensus $271.55M 05/16/22 Kore Group reports Q1 EPS (15c), consensus (9c) KORE Kore Group $2.71 / -0.03 (-1.09%) 03/29/22 Fly Intel: After-Hours Movers
Earnings	Soligenix reports Q2 EPS (6c), consensus (8c) » 07:34 08/12/22 08/12 07:34 08/12/22 07:34 SNGX Soligenix / + Reports Q2 revenue $0.4M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Events SNGX Soligenix / + 07/27/22 Soligenix receives FDA agreement on pediatric study plan for HyBryte in lymphoma 07/25/22 Soligenix signs license agreement with SERB Pharmaceuticals 07/20/22 Soligenix announces results of Phase 3 FLASH study of HyBryte 07/14/22 SERB Pharmaceuticals licenses antigen from Soligenix SNGX Soligenix / + 08/25/21 Alliance Global Partners Soligenix price target lowered to $3.75 from $5.75 at Alliance Global Partners 09/22/22 Soligenix, Inc.
Hot Stocks	Marathon Gold reports Q2 capex C$9.2M vs. C$4.7M last year » 07:33 08/12/22 08/12 07:33 08/12/22 07:33 MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) Matt Manson, President,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) 07/28/22 Marathon Gold publishes first annual sustainability report 07/18/22 Marathon Gold reports key stakeholder agreements for Valentine Gold Project 07/06/22 Marathon Gold announces updated MRE for Valentine Gold Project 06/15/22 Marathon Gold reports first 2022 drill results from Berry, Victory Deposits MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) 07/21/22 National Bank Marathon Gold price target lowered to C$2.50 from C$3.75 at National Bank 07/07/22 Canaccord Marathon Gold price target lowered to C$3.50 from C$3.60 at Canaccord 06/14/22 RBC Capital Marathon Gold price target lowered to C$3.50 from C$4 at RBC Capital 05/16/22 TD Securities Marathon Gold price target lowered to C$3.50 from C$4 at TD Securities MGDPF Marathon Gold $1.55 / -0.007 (-0.45%) 03/25/22 Marathon Gold reports Q4 net loss C$2.37M vs. C$2.88M last year
Recommendations	Taysha Gene Therapies price target lowered to $5 from $9 at Wedbush » 07:33 08/12/22 08/12 07:33 08/12/22 07:33 TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) Wedbush analyst Laura… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 08/11/22 Taysha Gene Therapies expects cash to fund expenses into 4Q23 05/16/22 Taysha Gene Therapies announces upcoming milestones 05/03/22 Taysha Gene Therapies receives orphan drug designation for TSHA-120 04/25/22 Taysha Gene Therapies announces oral presentations at IRSFT, ASCENT meetings TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 05/17/22 Chardan Taysha Gene Therapies price target lowered to $34 from $37 at Chardan 04/01/22 Truist Taysha Gene Therapies price target lowered to $35 from $60 at Truist 03/31/22 Chardan Taysha Gene Therapies price target lowered to $37 from $60 at Chardan 03/09/22 Baird Baird expects positive GAN guide for Taysha Gene Therapies, starts at Outperform TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 08/11/22 Taysha Gene Therapies reports Q2 EPS (84c) vs. ($1.09) last year 05/16/22 Taysha Gene Therapies reports Q1 EPS ($1.31), consensus ($1.07) 03/31/22 Taysha Gene Therapies reports Q4 EPS ($1.32), consensus ($1.25) TSHA Taysha Gene Therapies $3.96 / -0.95 (-19.35%) 03/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/03/22 6th Annual Genetic Medicines Conference
Recommendations	Fastly price target lowered to $25 from $35 at Raymond James » 07:32 08/12/22 08/12 07:32 08/12/22 07:32 FSLY Fastly $11.56 / -0.275 (-2.32%) Raymond James analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fastly names Todd Nightingale as CEO effective September 1 07/11/22 Fastly falls -14.0% 07/11/22 Fastly falls -11.4% 05/19/22 Fastly acquires Glitch, terms undisclosed FSLY Fastly $11.56 / -0.275 (-2.32%) 08/04/22 Craig-Hallum Fastly price target lowered to $13 from $19 at Craig-Hallum 07/22/22 Citi Fastly price target lowered to $10 from $14 at Citi 07/19/22 RBC Capital Fastly downgraded to Underperform from Sector Perform at RBC Capital 07/19/22 RBC Capital Fastly downgraded to Underperform from Sector Perform at RBC Capital FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fastly sees FY22 EPS (68c)-(63c), consensus (56c) 08/03/22 Fastly sees Q3 EPS (18c)-(15c), consensus (14c) 08/03/22 Fastly reports Q2 EPS (23c), consensus (17c) 08/03/22 Notable companies reporting after market close FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fly Intel: After-Hours Movers 07/11/22 What You Missed On Wall Street On Monday 07/11/22 What You Missed On Wall Street This Morning 05/05/22 What You Missed On Wall Street On Thursday FSLY Fastly $11.56 / -0.275 (-2.32%) 08/03/22 Fastly Inc options imply 15.3% move in share price post-earnings 07/01/22 Fastly Inc call volume above normal and directionally bullish 05/16/22 Fastly Inc call volume above normal and directionally bullish 05/04/22 Fastly Inc options imply 16.8% move in share price post-earnings
Recommendations	Leafly price target lowered to $4 from $12 at Cowen » 07:32 08/12/22 08/12 07:32 08/12/22 07:32 LFLY Leafly $2.25 / -0.15 (-6.25%) Cowen analyst Harrison… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options LFLY Leafly $2.25 / -0.15 (-6.25%) 06/24/22 Leafly set to join Russell 3000, Russell 200 Indexes 04/14/22 Leafly names Deidre Boulware Chief People Officer 03/24/22 Leafly Holdings trading resumes 03/24/22 Leafly Holdings trading halted, volatility trading pause LFLY Leafly $2.25 / -0.15 (-6.25%) 06:12 Today Benchmark Leafly price target lowered to $6.50 from $12.00 at Benchmark 05/20/22 Cowen Cowen starts Leafly with Outperform with its early mover advantage 05/20/22 Cowen Leafly initiated with an Outperform at Cowen 05/18/22 Oppenheimer Leafly initiated with a Perform at Oppenheimer LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly sees FY22 revenue $48M-$51M, three estimates $53.55M 08/11/22 Leafly reports Q2 EPS 37c, two estimates (12c) LFLY Leafly $2.25 / -0.15 (-6.25%) 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/18/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/07/22 Leafly LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly Holdings options imply 15.4% move in share price post-earnings 08/02/22 Leafly Holdings put volume heavy and directionally bearish 05/23/22 Largest borrow rate increases among liquid names 03/29/22 Leafly Holdings options imply 7.5% move in share price post-earnings
Downgrade	Sally Beauty downgraded to Market Perform at Cowen on risk to FY23 estimates » 07:32 08/12/22 08/12 07:32 08/12/22 07:32 SBH Sally Beauty $15.20 / +0.66 (+4.54%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SBH Sally Beauty $15.20 / +0.66 (+4.54%) 06/16/22 Sally Beauty falls -12.7% SBH Sally Beauty $15.20 / +0.66 (+4.54%) 05:56 Today Cowen Sally Beauty downgraded to Market Perform from Outperform at Cowen 06/29/22 Raymond James Raymond James cuts Sally Beauty to Underperform on exposure low-income consumer 06/29/22 Raymond James Sally Beauty downgraded to Underperform from Market Perform at Raymond James 06/16/22 Morgan Stanley Sally Beauty downgraded to Underweight from Equal Weight at Morgan Stanley SBH Sally Beauty $15.20 / +0.66 (+4.54%) 08/04/22 Sally Beauty lowers FY22 revenue growth view to down 2% from 0%-down 2% 08/04/22 Sally Beauty reports Q3 adjusted EPS 55c, consensus 59c 05/05/22 Sally Beauty lowers FY22 revenue growth view to 0%-down 2% from up 3%-4% 05/05/22 Sally Beauty reports Q2 adjusted EPS 47c, consensus 51c SBH Sally Beauty $15.20 / +0.66 (+4.54%) 06/29/22 What You Missed On Wall Street On Wednesday 06/29/22 What You Missed On Wall Street This Morning 06/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/16/22 What You Missed On Wall Street On Thursday
Downgrade	PagerDuty downgraded to Neutral from Buy at Monness Crespi » 07:31 08/12/22 08/12 07:31 08/12/22 07:31 PD PagerDuty $28.13 / -1.145 (-3.91%) Monness Crespi analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PD PagerDuty $28.13 / -1.145 (-3.91%) 06/29/22 PagerDuty CEO sells $2.11M in common stock 05/24/22 PagerDuty expands international presence to Japan 05/02/22 PagerDuty appoints Katherine Post Calvert as CMO 03/17/22 PagerDuty rises 15.3% PD PagerDuty $28.13 / -1.145 (-3.91%) 07/07/22 Canaccord PagerDuty initiated with a Buy at Canaccord 06/03/22 Craig-Hallum PagerDuty price target lowered to $37 from $45 at Craig-Hallum 06/03/22 Baird PagerDuty price target lowered to $40 from $47 at Baird 05/31/22 RBC Capital PagerDuty price target lowered to $41 from $46 at RBC Capital PD PagerDuty $28.13 / -1.145 (-3.91%) 06/02/22 PagerDuty sees FY23 EPS (21c)-(17c), consensus (20c) 06/02/22 PagerDuty sees Q2 EPS (9c)-(8c), consensus (8c) 06/02/22 PagerDuty reports Q1 EPS (4c), consensus (8c) 03/16/22 PagerDuty sees FY23 adjusted EPS (23c)-(17c), consensus (19c) PD PagerDuty $28.13 / -1.145 (-3.91%) 06/02/22 Fly Intel: After-Hours Movers 03/17/22 What You Missed On Wall Street On Thursday 03/17/22 What You Missed On Wall Street This Morning 03/16/22 Fly Intel: After-Hours Movers 09/01/22 PagerDuty - PD PD PagerDuty $28.13 / -1.145 (-3.91%) 06/02/22 PagerDuty options imply 11.5% move in share price post-earnings 03/16/22 PagerDuty options imply 16.4% move in share price post-earnings

Downgrade	TerrAscend downgraded to Neutral from Overweight at Cantor Fitzgerald » 07:30 08/12/22 08/12 07:30 08/12/22 07:30 TRSSF TerrAscend $2.40 / +0.11 (+4.80%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 06/02/22 TerrAscend debuts Cookies, Gage brands in New Jersey 03/09/22 TerrAscend to close Gage Growth acquisition on March 10 TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 07/22/22 Seaport Global TerrAscend initiated with a Buy at Seaport Global 02/09/22 Clarus TerrAscend price target lowered to C$14 from C$16.25 at Clarus 12/08/21 Cantor Fitzgerald TerrAscend price target raised to $7.65 from $6.70 at Cantor Fitzgerald 11/17/21 Stifel TerrAscend price target lowered to C$21 from C$23 at Stifel TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 04/11/22 NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 04/14/22 Here's What You Missed in Cannabis This Week
Downgrade	NextNav cut to Perform at Oppenheimer on capital needs » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 NN NextNav $3.39 / +0.02 (+0.59%) Oppenheimer analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NN NextNav $3.39 / +0.02 (+0.59%) 08/10/22 NextNav appoints Subin as new board member 07/07/22 NextNav enters partnership with VOS Systems 06/13/22 NextNav announces The Vitals App has joined NextNav partner ecosystem 05/19/22 NextNav, Vizsafe partner for vertical location services NN NextNav $3.39 / +0.02 (+0.59%) 06:32 Today Oppenheimer NextNav downgraded to Perform from Outperform at Oppenheimer 05/16/22 R.F. Lafferty NextNav price target lowered to $15 from $16 at R.F. Lafferty 05/13/22 B. Riley NextNav price target lowered to $14.25 from $17 at B. Riley 01/06/22 R.F. Lafferty NextNav initiated with a Buy at R.F. Lafferty NN NextNav $3.39 / +0.02 (+0.59%) 08/10/22 NextNav reports Q2 revenue $1.4M vs. $216,000 last year
Recommendations	Toast price target raised to $27 from $21 at Needham » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 TOST Toast $18.12 / -0.33 (-1.79%) Needham analyst Mayank… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance 07/26/22 Cathie Wood's ARK Investment bought 113K shares of Toast today 07/07/22 Toast acquires employee scheduling, communication solution Sling, no terms 05/13/22 Toast rises 15.2% TOST Toast $18.12 / -0.33 (-1.79%) 07:17 Today KeyBanc Toast price target raised to $25 from $18 at KeyBanc 05/17/22 Mizuho Toast price target lowered to $18 from $19 at Mizuho 05/13/22 Needham Toast price target lowered to $21 from $38 at Needham 05/13/22 Canaccord Toast price target lowered to $25 from $34 at Canaccord TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B 08/11/22 Toast sees Q3 revenue $700M-$730M, consensus $665.08M 08/11/22 Toast reports Q2 EPS (11c) vs (64c) last year 08/11/22 Notable companies reporting after market close 22 Sep TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Fly Intel: After-Hours Movers 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Fly Intel: Pre-market Movers TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast Inc options imply 11.3% move in share price post-earnings 05/12/22 Toast Inc options imply 21.6% move in share price post-earnings 03/04/22 Toast Inc put volume heavy and directionally bearish 02/15/22 Toast Inc options imply 15.0% move in share price post-earnings
Recommendations	Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 NKTX Nkarta $15.59 / -0.36 (-2.26%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/25/22 Nkarta promotes Ralph Brandenberger to Chief Technical Officer 04/25/22 Nkarta trading resumes 04/25/22 Nkarta trading halted, volatility trading pause 04/25/22 Nkarta announces preliminary dose finding data for two NK cell programs NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/28/22 Needham Nkarta initiated with a Buy at Needham 07/18/22 SVB Securities Nkarta initiated with an Outperform at SVB Securities 04/26/22 Stifel Nkarta's AML/NHL data 'a positive' for CAR-NK space, says Stifel 04/25/22 Cantor Fitzgerald Nkarta assumed with an Overweight at Cantor Fitzgerald NKTX Nkarta $15.59 / -0.36 (-2.26%) 08/11/22 Nkarta reports Q2 EPS (61c), consensus (60c) 05/12/22 Nkarta reports Q1 EPS (79c), consensus (72c) 03/17/22 Nkarta reports Q4 EPS (69c), consensus (90c) 26 Apr NKTX Nkarta $15.59 / -0.36 (-2.26%) 04/26/22 What You Missed On Wall Street On Tuesday 04/26/22 What You Missed On Wall Street This Morning 04/25/22 Fly Intel: After-Hours Movers 04/25/22 What You Missed On Wall Street On Monday NKTX Nkarta $15.59 / -0.36 (-2.26%) 05/04/22 Nkarta call volume above normal and directionally bullish 04/25/22 Unusually active option classes on open April 25th
Initiation	Mereo BioPharma initiated with an Overweight at Cantor Fitzgerald » 07:27 08/12/22 08/12 07:27 08/12/22 07:27 MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 07/05/22 Mereo BioPharma regains compliance with Nasdaq minimum bid price requirement 06/02/22 Mereo announces portfolio prioritization plan, sees cash runway into late 2024 06/02/22 Mereo BioPharma to present data update for Phase 1b/2 ACTIVATE study 05/26/22 Mereo BioPharma to present updated Phase 1b/2 data on Etigilimab and Nivolumab MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/06/22 Needham Mereo BioPharma price target lowered to $5 from $10 at Needham MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/17/22 AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports
Recommendations	Shattuck Labs price target lowered to $21 from $31 at Needham » 07:26 08/12/22 08/12 07:26 08/12/22 07:26 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) Needham analyst Chad… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024 05/12/22 Shattuck Labs sees cash, equivalents funding operations into 2H24 04/08/22 Shattuck Labs presents preclinical SL-9258 data at AACR 03/15/22 Shattuck Labs expects cash to fund operations into 2H24 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Citi Shattuck Labs initiated with a Buy at Citi 05/02/22 H.C. Wainwright Shattuck Labs initiated with a Buy at H.C. Wainwright STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs reports Q2 EPS (65c), consensus (59c) 05/12/22 Shattuck Labs reports Q1 EPS (58c), consensus (50c) 03/15/22 Shattuck Labs reports Q4 EPS 18c, two est. (43c) STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Lennar downgraded to Neutral from Outperform at Wedbush » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 LEN Lennar $87.78 / +0.47 (+0.54%) Wedbush analyst Jay… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options LEN Lennar $87.78 / +0.47 (+0.54%) 06/26/22 Fly Intel: Top five weekend stock stories 06/21/22 Housing market has cooled as expected, Lennar says 06/21/22 Lennar sees Q3 deliveries 17,000-18,500 03/17/22 Lennar raises FY gross margin view to 27.25%-28% from 27%-27.5% LEN Lennar $87.78 / +0.47 (+0.54%) 06:32 Today Wedbush Lennar downgraded to Neutral from Outperform at Wedbush 07/12/22 JPMorgan JPMorgan 'cautious and less constructive' on homebuilders, downgrades Lennar 07/12/22 JPMorgan Lennar downgraded to Neutral from Overweight at JPMorgan 06/22/22 UBS Lennar price target lowered to $106 from $108 at UBS LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 Lennar sees Q3 EPS $4.55-$5.45, consensus $4.78 06/21/22 Lennar reports Q2 EPS $4.49, consensus $3.98 03/17/22 Lennar sees Q2 EPS $3.80-$4.00, consensus $3.75 03/16/22 Lennar sees FY22 deliveries about 68,000 LEN Lennar $87.78 / +0.47 (+0.54%) 06/25/22 Lennar, Nucor among home-building and steel stocks worth a look, Barron's says 04/14/22 Mortgage rates spike to 5% amid post-pandemic price pressures, NY Times says LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 What You Missed On Wall Street On Tuesday 06/21/22 What You Missed On Wall Street This Morning 06/21/22 Fly Intel: Pre-market Movers 03/17/22 What You Missed On Wall Street On Thursday LEN Lennar $87.78 / +0.47 (+0.54%) 07/01/22 Early notable gainers among liquid option names on July 1st 06/23/22 Early notable gainers among liquid option names on June 23rd 06/22/22 Early notable gainers among liquid option names on June 22nd 05/25/22 Early notable gainers among liquid option names on May 25th
Hot Stocks	GreenLight Bioscences announces $109M financing » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) GreenLight Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) 08/01/22 GreenLight, Samsung Biologics complete run for mRNA production partnership 08/01/22 GreenLight Bioscences' COVID-19 vaccine completes first engineering run 07/29/22 GreenLight Bioscences to collaborate on COVID-19 vaccine development with NIH 03/14/22 GreenLight enters into licensing agreement with Serum Institute of India
Hot Stocks	ARC Group says RM2 continues to experience 'record demand' for BLOCKPal pallets » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 ARCW ARC Group $1.00 / + (+0.00%) ARC Group Worldwide… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Hot Stocks	Aptinyx announces NYX-2925 study did not achieve primary endpoint » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 APTX Aptinyx / + Aptinyx announced results… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options APTX Aptinyx / + 04/20/22 Aptinyx says NYX-783 data suggest potential as a treatment for PTSD 04/07/22 Aptinyx trading resumes 04/07/22 Aptinyx trading halted, news pending 04/07/22 Aptinyx announces NYX-2925 study did not achieve primary endpoint APTX Aptinyx / + 05/18/22 Piper Sandler Aptinyx price target lowered to $6 from $10 at Piper Sandler 04/14/22 H.C. Wainwright Aptinyx price target lowered to $2 from $8 at H.C. Wainwright 04/08/22 BMO Capital Aptinyx price target lowered to $6 from $12 at BMO Capital 04/08/22 Truist Aptinyx price target lowered to $5 from $12 at Truist APTX Aptinyx / + 08/04/22 Aptinyx reports Q2 EPS (26c), consensus (28c) 05/12/22 Aptinyx reports Q1 EPS (29c), consensus (30c) 03/23/22 Aptinyx reports Q4 EPS (29c), consensus (35c) APTX Aptinyx / + 03/23/22 Aptinyx options imply 6.9% move in share price post-earnings

Hot Stocks	Unity: UBX1325 injection led to clinically meaningful improvement in mean BCVA » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 UBX Unity Biotechnology / + UNITY Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology announces anticipated milestones 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Downgrade	Diebold downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 DBD Diebold $4.46 / -0.13 (-2.83%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Diebold rises 23.3% 05/10/22 Diebold expects to see cost savings of $150M in the next 12-18 months 03/17/22 Diebold: Shipments, sales into Russia suspended since start of Ukraine crisis DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Wedbush Wedbush upgrades Diebold, sees sales and earnings positioned to improve 07/08/22 Wedbush Diebold upgraded to Outperform from Neutral at Wedbush 05/10/22 JPMorgan Diebold downgraded to Neutral at JPMorgan after 'material' guidance cut 05/10/22 JPMorgan Diebold downgraded to Neutral from Overweight at JPMorgan DBD Diebold $4.46 / -0.13 (-2.83%) 08/02/22 Diebold lowers FY22 revenue view to $3.55B-$3.75B from $3.7B-$3.9B 08/02/22 Diebold reports Q2 non-GAAP EPS 38c, consensus (14c) 05/10/22 Diebold lowers FY22 revenue view to $3.7B-$3.9B from $4.0B-$4.2B 05/10/22 Diebold reports Q1 non-GAAP EPS ($1.61), consensus (21c) DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Plexus downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 PLXS Plexus $95.69 / +0.88 (+0.93%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PLXS Plexus $95.69 / +0.88 (+0.93%) 08/08/22 Plexus opens manufacturing facility in Bangkok, Thailand PLXS Plexus $95.69 / +0.88 (+0.93%) 07/29/22 Needham Plexus price target raised to $105 from $93 at Needham 07/27/22 Benchmark Plexus initiated with a Buy at Benchmark 06/07/22 Raymond James Plexus upgraded to Outperform from Market Perform at Raymond James 01/28/22 Needham Plexus price target lowered to $90 from $95 at Needham PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Plexus sees Q4 GAAP EPS $1.19-$1.35, consensus $1.10 07/27/22 Plexus reports Q3 adjusted EPS $1.33, consensus $1.10 04/27/22 Plexus reports Q2 EPS 95c, consensus 99c 03/07/22 Plexus reaffirms Q2 EPS guidance 76c-92c, consensus 99c PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/24/22 Plexus
Downgrade	Cognex downgraded to Underweight from Neutral at JPMorgan » 07:19 08/12/22 08/12 07:19 08/12/22 07:19 CGNX Cognex $48.48 / +0.54 (+1.13%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CGNX Cognex $48.48 / +0.54 (+1.13%) 06/09/22 Cognex discloses fire at primary manufacturing facility in Indonesia 03/03/22 Cognex authorizes up to $500M stock buyback program CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Needham Cognex price target lowered to $50 from $60 at Needham 08/03/22 Cowen Cognex price target lowered to $55 from $75 at Cowen 08/03/22 Stephens Cognex downgraded to Equal Weight at Stephens on logistics demand deteriorating 08/03/22 Stephens Cognex downgraded to Equal Weight from Overweight at Stephens CGNX Cognex $48.48 / +0.54 (+1.13%) 08/02/22 Cognex sees Q3 revenue $160M-$180M, consensus $290.25M 08/02/22 Cognex reports Q2 adjusted EPS 41c, consensus 41c 05/05/22 Cognex sees Q2 revenue $265M-$285M, consensus $292.72M 05/05/22 Cognex reports Q1 EPS 42c, consensus 38c CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/02/22 Fly Intel: After-Hours Movers 02/17/22 Fly Intel: After-Hours Movers
Recommendations	Six Flags price target lowered to $28 from $35 at Stifel » 07:18 08/12/22 08/12 07:18 08/12/22 07:18 SIX Six Flags $21.12 / -4.685 (-18.16%) Stifel analyst Steven… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags falls -22.5% 08/11/22 Six Flags falls -21.5% 08/11/22 Six Flags falls -18.1% 08/11/22 Six Flags reports Q2 attendance 6.7M vs. 8.5M a year ago, down 22% SIX Six Flags $21.12 / -4.685 (-18.16%) 05:44 Today KeyBanc Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2 08/11/22 KeyBanc Six Flags downgraded to Sector Weight from Overweight at KeyBanc 07/08/22 Citi Six Flags downgraded to Neutral from Buy at Citi 06/24/22 Stifel Six Flags price target lowered to $35 from $52 at Stifel SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags reports Q2 EPS 53c, consensus $1.02 08/10/22 Notable companies reporting before tomorrow's open 08/10/22 Notable companies reporting before tomorrow's open 05/12/22 Six Flags reports Q1 EPS (76c), consensus ($1.04) SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/11/22 Fly Intel: Pre-market Movers 07/21/22 Fly Intel: After-Hours Movers

Events

Earnings calls, analyst events, roadshows and more

CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CASI
Today at 08:00

Casi Pharmaceuticals - CASI Conference Calls
GTEC
Today at 08:00

Greenland Technologies - GTEC Conference Calls
VERO
Today at 08:00

Venus Concept - VERO Conference Calls
EVK
Today at 08:00

Ever-Glory - EVK Conference Calls
CMMB
Today at 08:00

Chemomab Therapeutics - CMMB Conference Calls
HUMA
Today at 08:00

Humacyte - HUMA Conference Calls
Today at 08:30

Import Prices M/M: July 2022 Government Event
Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

Alterity Therapeutics doses first patient in ATH434 Phase 2 trial

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access